Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome
Authors:
- 7 August 2015
- journal article
- research article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 31 (1) , 67-72
Abstract
The aim of this study was to analyze the long-term efficacy and safety of angiotensin-converting enzyme inhibitor (ACEi) and ACEi + angiotensin receptor blocker (ARB) treatments in a cohort of children with Alport syndrome (AS).Keywords
This publication has 15 references indexed in Scilit:
- Losartan and enalapril are comparable in reducing proteinuria in children with Alport syndromePediatric Nephrology, 2012
- Genotype–phenotype correlations in 17 Chinese patients with autosomal recessive Alport syndromeAmerican Journal of Medical Genetics Part A, 2012
- Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research CollaborativePediatric Nephrology, 2012
- Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancyKidney International, 2012
- Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trialNephrology Dialysis Transplantation, 2011
- Drugs controlling proteinuria of patients with Alport syndromeWorld Journal of Pediatrics, 2009
- Novel COL4A5, COL4A4, and COL4A3 mutations in Alport syndromeHuman Mutation, 2005
- Enalapril in children with Alport syndromePediatric Nephrology, 2004
- Identification of mutations in the α3(IV) and α4(IV) collagen genes in autosomal recessive Alport syndromeNature Genetics, 1994
- Identification of Mutations in the COL4A5 Collagen Gene in Alport SyndromeScience, 1990